Kymera Therapeutics to Present at Upcoming May Investor Conferences

Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR) has announced its participation in two upcoming investor conferences. The company will present at the BofA Securities 2021 Virtual Healthcare Conference on May 13 at 3:30 p.m. ET and at the UBS Global Healthcare Virtual Conference on May 25 at 12:00 p.m. ET. Live webcasts will be available on Kymera's website, with archived replays for 30 days. Kymera focuses on targeted protein degradation to address challenging disease targets using its Pegasus™ platform, aiming to develop new treatments for various immune-inflammatory diseases and cancers.

WATERTON, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at the upcoming investor conferences:

• BofA Securities 2021 Virtual Healthcare Conference on Thursday, May 13 at 3:30 p.m. ET
• UBS Global Healthcare Virtual Conference on Tuesday, May 25 at 12:00 p.m. ET

A live webcast of each event will be available under "Events and Presentations" in the Investors section of the Company's website at www.kymeratx.com. Archived webcast replays of the presentations will also be available on the website for approximately 30 days.

About Kymera Therapeutics
Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted protein degradation platform harnesses the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. Kymera’s initial programs are IRAK4, IRAKIMiD, and STAT3, which each address high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. For more information, visit www.kymeratx.com.

Investor Contact:
Paul Cox
VP, Investor Relations and Communications
pcox@kymeratx.com
917-754-0207

Media Contact:
Lissette L. Steele
Verge Scientific Communications for Kymera Therapeutics
lsteele@vergescientific.com
202-930-4762

FAQ

What dates will Kymera Therapeutics present at investor conferences?

Kymera Therapeutics will present at the BofA Securities 2021 Virtual Healthcare Conference on May 13, 2021, at 3:30 p.m. ET and at the UBS Global Healthcare Virtual Conference on May 25, 2021, at 12:00 p.m. ET.

Where can I watch the presentations of KYMR at the healthcare conferences?

The presentations can be watched live on Kymera Therapeutics' website. Archived webcasts will also be available for approximately 30 days.

What is Kymera Therapeutics known for?

Kymera Therapeutics is known for advancing targeted protein degradation to deliver novel small molecule medicines, focusing on treating previously intractable disease targets.

What is the Pegasus™ platform by Kymera Therapeutics?

The Pegasus™ platform harnesses the body’s natural protein recycling mechanisms to degrade disease-causing proteins, targeting previously inaccessible therapeutic pathways.

What are some initial programs of Kymera Therapeutics?

Kymera's initial programs include IRAK4, IRAKIMiD, and STAT3, which target high-impact areas within the IL-1R/TLR and JAK/STAT pathways.